Compare Biogen Inc (BIIB) vs Sea Limited (SE) Price & Performance

Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.

The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.

Sea Limited (SE) trades at $114.80, up 1.21% with strong technical momentum as the stock approaches key resistance levels. The company demonstrates robust fundamental growth with Q2 2026 revenue of $7.8 billion (up 48% YoY) and net income growth of 11%, supported by diversified performance across e-commerce, fintech, and gaming segments. Analyst consensus remains strongly bullish with a $128.33 price target, though valuation metrics appear elevated with a P/E of 50.78.

SE presents compelling growth prospects with accelerating revenue and expanding profitability, but faces risks from increased investment spending and competitive pressures. The stock's current technical overbought condition near resistance suggests potential near-term consolidation before further upside. Wall Street's overwhelming buy rating (70% of analysts) supports the positive long-term outlook despite premium valuation concerns.